DRF History

DRF expanded its capabilities by launching Contract Research Organization (CRO) services, enhancing its role in providing specialized research support to the pharmaceutical and healthcare industries. Additionally, DRF partnered with Oxford University on a collaborative oncology research project aimed at identifying and validating novel therapeutic targets.

DRF undertook a significant expansion of its facility to support its growing research portfolio. As part of this development, DRF has initiated Good Laboratory Practice (GLP)-compliant studies to ensure the highest standards in research quality and regulatory alignment. This expansion included the creation of state-of-the-art laboratories dedicated to Cell Biology, Pharmacology, Drug Metabolism and Pharmacokinetics (DMPK), Toxicology and Genotoxicology, enhancing DRF's capacity to conduct comprehensive preclinical studies. These new labs not only support DRF's internal projects but also reinforced its CRO services, enabling collaborations across the pharmaceutical and biotechnology sectors. Through this expansion, DRF positioned itself as a premier center for advanced preclinical research and drug discovery and development.

DRF achieved a series of prestigious certifications and recognitions that underscore its commitment to excellence in research and compliance. The facility has obtained ISO certification, ensuring adherence to rigorous quality management standards. Additionally, it has earned SIRO (Scientific and Industrial Research Organization) recognition from the Department of Scientific and Industrial Research (DSIR), acknowledging its contributions to innovation and research. DRF's accreditation with OECD Good Laboratory Practice (GLP) further validates its robust protocols for study quality and regulatory compliance. Moreover, the facility has been awarded AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care) accreditation, emphasizing its dedication to ethical and high-standard animal care in research. Together, these accreditations establish DRF as a highly credible and trusted research institution in the healthcare and life sciences sector.

DRF expanded its analytical laboratory, enhancing its capabilities to support more sophisticated and comprehensive research activities. This upgraded facility is equipped with advanced instrumentation and cutting-edge technology, allowing for precise and reliable analysis of complex compounds.

DRF successfully achieved GLP recertification, reaffirming its adherence to stringent quality and compliance standards in laboratory practices. This recertification validates DRF's consistent commitment to regulatory excellence and ensures that all studies conducted meet the highest standards for accuracy, reliability, and safety. By maintaining GLP compliance, DRF continues to build trust with its partners and stakeholders, reinforcing its role as a reliable and compliant research organization within the pharmaceutical and healthcare sectors.

DRF once again achieved GLP recertification, highlighting its consistent dedication to high-quality, compliant laboratory practices. This recurring certification emphasizes DRF's ongoing commitment to upholding stringent regulatory standards, ensuring reliable, reproducible, and accurate results across all research activities. This achievement further solidifies DRF's reputation as a trusted leader in the life sciences and healthcare research sectors.

The Pharmacology Department at Dabur Research Foundation proudly achieved Good Laboratory Practices (GLP) compliance certification. Additionally, DRF successfully registered its Test Facility with the USFDA under FDA Establishment Identification Number 3006607414, marking a significant milestone in regulatory excellence.